Sanjiv J Shah

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5103296/publications.pdf

Version: 2024-02-01

		4653	5677
451	33,085	85	162
papers	citations	h-index	g-index

461	461	461	24773
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Spironolactone for Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine, 2014, 370, 1383-1392.	13.9	1,993
2	Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. New England Journal of Medicine, 2018, 379, 1007-1016.	13.9	1,558
3	Angiotensinâ€“Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine, 2019, 381, 1609-1620.	13.9	1,485
4	Phenomapping for Novel Classification of Heart Failure With Preserved Ejection Fraction. Circulation, 2015, 131, 269-279.	1.6	763
5	Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial. Circulation, 2015, 131, 34-42.	1.6	758
6	Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction. Circulation, 2016, 134, 73-90.	1.6	747
7	Fully Automated Echocardiogram Interpretation in Clinical Practice. Circulation, 2018, 138, 1623-1635.	1.6	563
8	Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine, 2015, 373, 2314-2324.	13.9	453
9	Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet, The, 2011, 378, 498-506.	6.3	446
10	Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. European Heart Journal, 2016, 37, 455-462.	1.0	396
11	Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF. European Heart Journal, 2018, 39, 3439-3450.	1.0	375
12	Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. Circulation, 2015, 132, 402-414.	1.6	371
13	Genotype and Phenotype of Transthyretin Cardiac Amyloidosis. Journal of the American College of Cardiology, 2016, 68, 161-172.	1.2	338
14	Inaccuracy of Doppler Echocardiographic Estimates of Pulmonary Artery Pressures in Patients With Pulmonary Hypertension. Chest, 2011, 139, 988-993.	0.4	328
15	The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nature Medicine, 2021, 27, 1954-1960.	15.2	299
16	RV Contractile Function and its Coupling to Pulmonary Circulation in Heart Failure With PreservedÂEjectionÂFraction. JACC: Cardiovascular Imaging, 2017, 10, 1211-1221.	2.3	297
17	Management of Pulmonary ArterialÂHypertension. Journal of the American College of Cardiology, 2015, 65, 1976-1997.	1.2	296
18	Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2014, 7, 104-115.	1.6	288

#	Article	IF	Citations
19	Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction. JAMA - Journal of the American Medical Association, 2015, 314, 2251.	3.8	288
20	Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study. European Heart Journal, 2017, 38, 1119-1127.	1.0	285
21	Whole-genome association study identifies STK39 as a hypertension susceptibility gene. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 226-231.	3.3	280
22	Prognostic Utility and Clinical Significance of Cardiac Mechanics in Heart Failure With Preserved Ejection Fraction. Circulation: Cardiovascular Imaging, 2016, 9, .	1.3	268
23	Developing Therapies for Heart Failure WithÂPreservedÂEjection Fraction. JACC: Heart Failure, 2014, 2, 97-112.	1.9	267
24	The Emerging Epidemic of Heart Failure with Preserved Ejection Fraction. Current Heart Failure Reports, 2013, 10, 401-410.	1.3	266
25	The Association of Obesity and Cardiometabolic Traits With IncidentÂHFpEF and HFrEF. JACC: Heart Failure, 2018, 6, 701-709.	1.9	254
26	Clinical Characteristics of Pulmonary Hypertension in Patients With Heart Failure and Preserved Ejection Fraction. Circulation: Heart Failure, 2011, 4, 257-265.	1.6	253
27	Endogenous Sex Hormones and IncidentÂCardiovascular Disease in Post-Menopausal Women. Journal of the American College of Cardiology, 2018, 71, 2555-2566.	1.2	250
28	Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction. Circulation, 2020, 141, 338-351.	1.6	244
29	A Test in Context. Journal of the American College of Cardiology, 2017, 69, 1451-1464.	1.2	240
30	Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 16-37.	2.9	239
31	Research Priorities for Heart Failure With Preserved Ejection Fraction. Circulation, 2020, 141, 1001-1026.	1.6	239
32	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2â€"evidence base and standardized methods of imaging. Journal of Nuclear Cardiology, 2019, 26, 2065-2123.	1.4	230
33	Ventricular Wall Compliance: A Marker and Diagnostic Marker in Pulmonary Hypertensionâ€â€Conflicts of interest: Dr. Gomberg-Maitland has received research grant support from Actelion Pharmaceuticals Ltd., Allschwil, Switzerland; CoTherix, Inc., South San Francisco, California; Encysive Pharmaceuticals Inc., Houston, Texas; Gilead Sciences Inc., Foster City, California; Eli Lilly/ICOS, Indianapolis, Indiana; Pfizer Inc., New York, New York; and United Therapeutics, Silver Spring, Maryland. Dr. Gomberg-Mai. American Journal of Cardiology, 2009, 104, 868-872.	0.7	229
34	Predicting Heart Failure With Preserved and Reduced Ejection Fraction. Circulation: Heart Failure, 2016, 9, .	1.6	227
35	Prognostic Relevance of Left Atrial Dysfunction in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2016, 9, e002763.	1.6	224
36	Cardiovascular Risk Assessment of the Liver Transplant Candidate. Journal of the American College of Cardiology, 2011, 58, 223-231.	1.2	223

#	Article	IF	Citations
37	Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: A populationâ€based study. Hepatology, 2015, 62, 773-783.	3.6	221
38	Cardiac Structure and Function and Prognosis in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2014, 7, 740-751.	1.6	218
39	Prevalence, Clinical Phenotype, and Outcomes Associated With Normal B-Type Natriuretic Peptide Levels in Heart Failure With Preserved Ejection Fraction. American Journal of Cardiology, 2012, 110, 870-876.	0.7	214
40	Regulation of Hypoxia-induced Pulmonary Hypertension by Vascular Smooth Muscle Hypoxia-Inducible Factor-1Î±. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 314-324.	2.5	209
41	Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure]). Circulation, 2018, 137, 364-375.	1.6	206
42	Evaluating the Atrial Myopathy Underlying Atrial Fibrillation. Circulation, 2015, 132, 278-291.	1.6	196
43	Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the <scp>DELIVER</scp> trial. European Journal of Heart Failure, 2021, 23, 1217-1225.	2.9	195
44	Mode of Death in Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 2017, 69, 556-569.	1.2	193
45	Effect of Inorganic Nitrite vs Placebo on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction. JAMA - Journal of the American Medical Association, 2018, 320, 1764.	3.8	187
46	Association of Cardiovascular Biomarkers With Incident Heart Failure With Preserved and Reduced Ejection Fraction. JAMA Cardiology, 2018, 3, 215.	3.0	186
47	Transthyretin Stabilization by AG10 in Symptomatic Transthyretin AmyloidÂCardiomyopathy. Journal of the American College of Cardiology, 2019, 74, 285-295.	1.2	170
48	Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction. JAMA - Journal of the American Medical Association, 2020, 324, 1512.	3.8	170
49	Prognostic Importance of Pathophysiologic Markers in Patients With Heart Failure and Preserved Ejection Fraction. Circulation: Heart Failure, 2014, 7, 288-299.	1.6	166
50	Use of Real Time Three-Dimensional Transesophageal Echocardiography in Intracardiac Catheter Based Interventions. Journal of the American Society of Echocardiography, 2009, 22, 865-882.	1.2	157
51	Long-Term Cardiovascular Risks Associated With AdverseÂPregnancyÂOutcomes. Journal of the American College of Cardiology, 2019, 73, 2106-2116.	1.2	156
52	Heart Failure With Preserved Ejection Fraction. JAMA - Journal of the American Medical Association, 2008, 300, 431.	3.8	154
53	Baseline Characteristics of Patients in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial. Circulation: Heart Failure, 2013, 6, 184-192.	1.6	154
54	Molecular Signatures in Skin Associated with Clinical Improvement during Mycophenolate Treatment in Systemic Sclerosis. Journal of Investigative Dermatology, 2013, 133, 1979-1989.	0.3	150

#	Article	IF	Citations
55	Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy. Circulation, 2020, 141, 1214-1224.	1.6	147
56	Association of chronic kidney disease with abnormal cardiac mechanics and adverse outcomes in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure, 2016, 18, 103-112.	2.9	140
57	The potential role and rationale for treatment of heart failure with sodiumâ€“glucose coâ€transporter 2 inhibitors. European Journal of Heart Failure, 2017, 19, 1390-1400.	2.9	139
58	Echocardiographic Features of PatientsÂWith HeartÂFailure and PreservedÂLeft Ventricular Ejection Fraction. Journal of the American College of Cardiology, 2019, 74, 2858-2873.	1.2	138
59	Endomyocardial Biopsy Characterization of HeartÂFailure With Preserved EjectionÂFraction and Prevalence of Cardiac Amyloidosis. JACC: Heart Failure, 2020, 8, 712-724.	1.9	138
60	The HFpEF Obesity Phenotype. Journal of the American College of Cardiology, 2016, 68, 200-203.	1.2	130
61	Cardiac involvement and treatment-related mortality after non-myeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for patients with systemic sclerosis: a retrospective analysis. Lancet, The, 2013, 381, 1116-1124.	6.3	129
62	Interaction Between Spironolactone and Natriuretic Peptides in Patients With HeartÂFailure and Preserved EjectionÂFraction. JACC: Heart Failure, 2017, 5, 241-252.	1.9	129
63	Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: A pooled analysis of 3 clinical trials. American Heart Journal, 2014, 167, 853-860.e4.	1.2	128
64	Phenotypic Spectrum of Heart Failure with Preserved Ejection Fraction. Heart Failure Clinics, 2014, 10, 407-418.	1.0	126
65	Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: Results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: a Randomized Controlled Trial in Patients Hospitalized with Heart Failure (HORIZON-HF) trial. American Heart Journal, 2009, 157, 1035-1041.	1.2	124
66	One-Year Safety and Clinical Outcomes of a Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (REDUCE LAP-HF I) Trial. JAMA Cardiology, 2018, 3, 968.	3.0	121
67	Rationale and design of the <scp>SOluble</scp> guanylate Cyclase <scp>stimulatoR</scp> in <scp>heArT failurE</scp> Studies (<scp>SOCRATES</scp>). European Journal of Heart Failure, 2014, 16, 1026-1038.	2.9	119
68	Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. Circulation: Heart Failure, 2018, 11, e004962.	1.6	117
69	Proteomic Evaluation of the Comorbidity-Inflammation Paradigm in Heart Failure With Preserved Ejection Fraction. Circulation, 2020, 142, 2029-2044.	1.6	117
70	Association of Serum Creatinine With Abnormal Hemodynamics and Mortality in Pulmonary Arterial Hypertension. Circulation, 2008, 117, 2475-2483.	1.6	116
71	Four-dimensional flow assessment of pulmonary artery flow and wall shear stress in adult pulmonary arterial hypertension: Results from two institutions. Magnetic Resonance in Medicine, 2015, 73, 1904-1913.	1.9	116
72	Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 6	6.3	112

#	Article	IF	Citations
73	Effects of an Interatrial Shunt on Rest and Exercise Hemodynamics: Results of a Computer Simulation in Heart Failure. Journal of Cardiac Failure, 2014, 20, 212-221.	0.7	111
74	Quality of life in heart failure with preserved ejection fraction: importance of obesity, functional capacity, and physical inactivity. European Journal of Heart Failure, 2020, 22, 1009-1018.	2.9	111
75	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2â€"Evidence Base and Standardized Methods of Imaging. Journal of Cardiac Failure, 2019, 25, e1-e39.	0.7	107
76	10-Year Risk Equations for Incident HeartÂFailure in the General Population. Journal of the American College of Cardiology, 2019, 73, 2388-2397.	1.2	107
77	Real-Time Three-Dimensional Transesophageal Echocardiography of the Left Atrial Appendage: Initial Experience in the Clinical Setting. Journal of the American Society of Echocardiography, 2008, 21, 1362-1368.	1.2	106
78	Large-scale genome-wide analysis identifies genetic variants associated with cardiac structure and function. Journal of Clinical Investigation, 2017, 127, 1798-1812.	3.9	106
79	Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial. Circulation, 2022, 145, 184-193.	1.6	106
80	Heart Failure With Preserved Ejection Fraction Expert Panel Report. JACC: Heart Failure, 2018, 6, 619-632.	1.9	103
81	Coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction. American Journal of Physiology - Heart and Circulatory Physiology, 2018, 314, H1033-H1042.	1.5	101
82	Validation of the HFAâ€PEFF score for the diagnosis of heart failure with preserved ejection fraction. European Journal of Heart Failure, 2020, 22, 413-421.	2.9	101
83	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2â€"Diagnostic criteria and appropriate utilization. Journal of Nuclear Cardiology, 2020, 27, 659-673.	1.4	97
84	A null mutation in SERPINE1 protects against biological aging in humans. Science Advances, 2017, 3, eaao1617.	4.7	95
85	Predictors and outcomes of heart failure with midâ€range ejection fraction. European Journal of Heart Failure, 2018, 20, 651-659.	2.9	91
86	Ultrastructural and cellular basis for the development of abnormal myocardial mechanics during the transition from hypertension to heart failure. American Journal of Physiology - Heart and Circulatory Physiology, 2014, 306, H88-H100.	1.5	90
87	Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning. Heart, 2020, 106, 342-349.	1.2	89
88	Systemic sclerosis and the heart. Current Opinion in Rheumatology, 2011, 23, 545-554.	2.0	88
89	Cardiopulmonary assessment of patients with systemic sclerosis for hematopoietic stem cell transplantation: recommendations from the European Society for Blood and Marrow Transplantation Autoimmune Diseases Working Party and collaborating partners. Bone Marrow Transplantation, 2017, 52, 1495-1503.	1.3	88
90	Intensive Lipid-Lowering With Atorvastatin for Secondary Prevention in Patients After Coronary Artery Bypass Surgery. Journal of the American College of Cardiology, 2008, 51, 1938-1943.	1.2	87

#	Article	IF	Citations
91	Metaâ€Analysis Global Group in Chronic (MAGGIC) Heart Failure Risk Score: Validation of a Simple Tool for the Prediction of Morbidity and Mortality in Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association, 2018, 7, e009594.	1.6	87
92	Exercise Intolerance in Older Adults WithÂHeartÂFailure With Preserved EjectionÂFraction. Journal of the American College of Cardiology, 2021, 78, 1166-1187.	1.2	87
93	Pulmonary Effective Arterial Elastance as a Measure of Right Ventricular Afterload and Its Prognostic Value in Pulmonary Hypertension Due to Left Heart Disease. Circulation: Heart Failure, 2018, 11, e004436.	1.6	85
94	Patientâ€reported outcomes in the <scp>SOluble</scp> guanylate Cyclase <scp>stimulatoR</scp> in <scp>heArT failurE patientS</scp> with <scp>PRESERVED</scp> ejection fraction (<scp>SOCRATESâ€PRESERVED</scp>) study. European Journal of Heart Failure, 2017, 19, 782-791.	2.9	84
95	Age dependent associations of risk factors with heart failure: pooled population based cohort study. BMJ, The, 2021, 372, n461.	3.0	83
96	Myocardial Strain in the Assessment of Patients With Heart Failure. JAMA Cardiology, 2019, 4, 287.	3.0	82
97	Prevalence, Clinical Characteristics, and Outcomes Associated With Eccentric Versus Concentric Left Ventricular Hypertrophy in Heart Failure With Preserved Ejection Fraction. American Journal of Cardiology, 2013, 112, 1158-1164.	0.7	81
98	Heart failure with preserved ejection fraction: recent concepts in diagnosis, mechanisms and management. Heart, 2022, 108, 1342-1350.	1.2	81
99	Matchmaking for the Optimization of Clinical Trials of Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 2013, 62, 1339-1342.	1.2	80
100	Physical Activity and Prognosis in the TOPCAT Trial (Treatment of Preserved Cardiac Function Heart) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.6	80
101	Effect of Praliciguat on Peak Rate of Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction. JAMA - Journal of the American Medical Association, 2020, 324, 1522.	3.8	79
102	Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEF. Journal of the American College of Cardiology, 2020, 76, 503-514.	1.2	77
103	Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction. JACC: Heart Failure, 2022, 10, 184-197.	1.9	75
104	Spectrum of epidemiological and clinical findings in patients with heart failure with preserved ejection fraction stratified by study design: a systematic review. European Journal of Heart Failure, 2016, 18, 54-65.	2.9	73
105	Artificial intelligence-enabled fully automated detection of cardiac amyloidosis using electrocardiograms and echocardiograms. Nature Communications, 2021, 12, 2726.	5.8	73
106	MR and CT Imaging for the Evaluation ofÂPulmonary Hypertension. JACC: Cardiovascular Imaging, 2016, 9, 715-732.	2.3	72
107	Longitudinal Association of Nonâ€Alcoholic Fatty Liver Disease With Changes in Myocardial Structure and Function: The CARDIA Study. Journal of the American Heart Association, 2020, 9, e014279.	1.6	72
108	Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction. JAMA - Journal of the American Medical Association, 2021, 326, 1919.	3.8	72

#	Article	IF	Citations
109	Prognostic Value of Left Ventricular End-Systolic Volume Index as a Predictor of Heart Failure Hospitalization in Stable Coronary Artery Disease: Data from the Heart and Soul Study. Journal of the American Society of Echocardiography, 2009, 22, 190-197.	1.2	71
110	Left atrial function in heart failure with preserved ejection fraction: a systematic review and metaâ€analysis. European Journal of Heart Failure, 2020, 22, 472-485.	2.9	71
111	COVID-19 and Heart Failure With Preserved Ejection Fraction. JAMA - Journal of the American Medical Association, 2020, 324, 1499.	3.8	71
112	Pulmonary Hypertension. JAMA - Journal of the American Medical Association, 2012, 308, 1366.	3.8	70
113	Association of Low-Grade Albuminuria With Adverse Cardiac Mechanics. Circulation, 2014, 129, 42-50.	1.6	70
114	Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. Circulation: Heart Failure, 2015, 8, 1052-1058.	1.6	70
115	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2â€"Diagnostic Criteria and Appropriate Utilization. Journal of Cardiac Failure, 2019, 25, 854-865.	0.7	70
116	Effects of Interatrial Shunt on Pulmonary Vascular Function in HeartÂFailure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 2019, 74, 2539-2550.	1.2	69
117	Adjudicated Heart Failure in HIVâ€Infected and Uninfected Men and Women. Journal of the American Heart Association, 2018, 7, e009985.	1.6	68
118	Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure, 2018, 6, 689-697.	1.9	68
119	Impact of Malnutrition Using Geriatric Nutritional Risk Index in HeartÂFailure With Preserved Ejection Fraction. JACC: Heart Failure, 2019, 7, 664-675.	1.9	68
120	Characterization of the Obese Phenotype of Heart Failure With Preserved Ejection Fraction: A RELAX Trial Ancillary Study. Mayo Clinic Proceedings, 2019, 94, 1199-1209.	1.4	68
121	Pulmonary Arterial Hypertension: Diagnosis, Treatment, and Novel Advances. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 1472-1487.	2.5	68
122	Diagnosis and Management of Heart Failure with Preserved Ejection Fraction: 10 Key Lessons. Current Cardiology Reviews, 2014, 11, 42-52.	0.6	68
123	High-Sensitivity C-Reactive Protein and Parameters of Left Ventricular Dysfunction. Journal of Cardiac Failure, 2006, 12, 61-65.	0.7	67
124	Left Atrial Decompression Pump forÂSevere Heart Failure With PreservedÂEjection Fraction. JACC: Heart Failure, 2015, 3, 275-282.	1.9	67
125	Albuminuria Is Independently Associated With Cardiac Remodeling, Abnormal Right and Left Ventricular Function, and Worse Outcomes in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure, 2014, 2, 586-596.	1.9	66
126	Precision Medicine for Heart Failure with Preserved Ejection Fraction: An Overview. Journal of Cardiovascular Translational Research, 2017, 10, 233-244.	1.1	66

#	Article	IF	Citations
127	Association of Central Adiposity With Adverse Cardiac Mechanics. Circulation: Cardiovascular Imaging, 2016, 9, .	1.3	65
128	Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE120008193.	1.6	65
129	Plasminogen Activator Inhibitor Type I Controls Cardiomyocyte Transforming Growth Factor-Î² and Cardiac Fibrosis. Circulation, 2017, 136, 664-679.	1.6	64
130	Sex hormone levels and change in left ventricular structure among men and post-menopausal women: The Multi-Ethnic Study of Atherosclerosis (MESA). Maturitas, 2018, 108, 37-44.	1.0	64
131	Câ€reactive protein, diastolic dysfunction, and risk of heart failure in patients with coronary disease: Heart and Soul Study. European Journal of Heart Failure, 2008, 10, 63-69.	2.9	62
132	Carbon monoxide diffusing capacity and mortality in pulmonary arterial hypertension. Journal of Heart and Lung Transplantation, 2010, 29, 181-187.	0.3	62
133	Phenomapping for the Identification of Hypertensive Patients with the Myocardial Substrate for Heart Failure with Preserved Ejection Fraction. Journal of Cardiovascular Translational Research, 2017, 10, 275-284.	1.1	61
134	Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBIâ€"Cardiovascular Medical Research and Education Fund Workshop Report. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1661-1670.	2.5	59
135	Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy) Tj ETQq1 1 0.784314 rgBT /Ov	1.6	59
136	Temporal Trends in Prevalence and Prognostic Implications of Comorbidities Among Patients With Acute Decompensated Heart Failure. Circulation, 2020, 142, 230-243.	1.6	59
137	Usefulness of Electrocardiographic QT Interval to Predict Left Ventricular Diastolic Dysfunction. American Journal of Cardiology, 2011, 108, 1760-1766.	0.7	57
138	Diastolic Electromechanical Coupling. Circulation: Arrhythmia and Electrophysiology, 2012, 5, 537-543.	2.1	56
139	Effects of Ranolazine on Exercise Capacity, Right Ventricular Indices, and Hemodynamic Characteristics in Pulmonary Arterial Hypertension: A Pilot Study. Pulmonary Circulation, 2015, 5, 547-556.	0.8	56
140	Sudden Death in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure, 2018, 6, 653-661.	1.9	56
141	A machine learning model for identifying patients at risk for wild-type transthyretin amyloid cardiomyopathy. Nature Communications, 2021, 12, 2725.	5.8	56
142	Loss of Lung Health from Young Adulthood and Cardiac Phenotypes in Middle Age. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 76-85.	2.5	54
143	Atrial fibrillation in heart failure with preserved ejection fraction: Insights into mechanisms and therapeutics. , 2017, 176, 32-39.		54
144	Sex-Specific Associations of Cardiovascular Risk Factors and Biomarkers With Incident HeartÂFailure. Journal of the American College of Cardiology, 2020, 76, 1455-1465.	1.2	54

#	Article	IF	Citations
145	Heart Failure in North America. Current Cardiology Reviews, 2013, 9, 128-146.	0.6	54
146	Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart Failure. Circulation, 2022, 145, 1592-1604.	1.6	54
147	Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in HeartÂFailure With Preserved Ejection Fraction. JACC: Heart Failure, 2020, 8, 372-381.	1.9	53
148	Repolarization Heterogeneity: Beyond the QT Interval. Journal of the American Heart Association, 2016, 5, .	1.6	52
149	Plasma Tryptophan-Kynurenine Metabolites Are Altered in Human Immunodeficiency Virus Infection and Associated With Progression of Carotid Artery Atherosclerosis. Clinical Infectious Diseases, 2018, 67, 235-242.	2.9	52
150	Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure. Circulation: Heart Failure, 2016, 9, .	1.6	51
151	Macrophages in Heart Failure with Reduced versus Preserved Ejection Fraction. Trends in Molecular Medicine, 2019, 25, 328-340.	3.5	51
152	Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic KidneyÂDisease. JACC: Heart Failure, 2019, 7, 25-32.	1.9	51
153	Text Mining of the Electronic Health Record: An Information Extraction Approach for Automated Identification and Subphenotyping of HFpEF Patients for Clinical Trials. Journal of Cardiovascular Translational Research, 2017, 10, 313-321.	1.1	50
154	Role of PAI-1 in hepatic steatosis and dyslipidemia. Scientific Reports, 2021, 11, 430.	1.6	50
155	Statins in the prevention of venous thromboembolism: A meta-analysis of observational studies. Thrombosis Research, 2011, 128, 422-430.	0.8	49
156	Lack of Association Between HeartÂFailure and Incident Cancer. Journal of the American College of Cardiology, 2018, 71, 1501-1510.	1.2	49
157	Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spironolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial. Journal of Cardiac Failure, 2018, 24, 313-320.	0.7	49
158	Prevalence, prognosis, and factors associated with left ventricular diastolic dysfunction in systemic sclerosis. Clinical and Experimental Rheumatology, 2012, 30, S30-7.	0.4	49
159	Right Heart Structural Changes Are Independently Associated with Exercise Capacity in Non-Severe COPD. PLoS ONE, 2011, 6, e29069.	1.1	48
160	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2â€"Evidence Base and Standardized Methods of Imaging. Circulation: Cardiovascular Imaging, 2021, 14, e000029.	1.3	48
161	INDIE-HFpEF (Inorganic Nitrite Delivery to Improve Exercise Capacity in Heart Failure With Preserved) Tj ETQq1 1 0.784314 rgBT /Over	1.6	47
162	Effect of Neladenoson Bialanate on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction. JAMA - Journal of the American Medical Association, 2019, 321, 2101.	3.8	47

#	Article	IF	Citations
163	Association of Serum Triiodothyronine With B-Type Natriuretic Peptide and Severe Left Ventricular Diastolic Dysfunction in Heart Failure With Preserved Ejection Fraction. American Journal of Cardiology, 2012, 110, 234-239.	0.7	46
164	Exploring New Endpoints for Patients With Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2016, 9, .	1.6	46
165	1H, 13C and 15N NMR assignments and solution secondary structure of rat Apo-S100Î². Journal of Biomolecular NMR, 1995, 6, 171-179.	1.6	45
166	Burden of Systolic and Diastolic Left Ventricular Dysfunction Among Hispanics in the United States. Circulation: Heart Failure, 2016, 9, e002733.	1.6	45
167	Constitutive Expression of a Dominant-Negative TGF-Î² Type II Receptor in the Posterior Left Atrium Leads to Beneficial Remodeling of Atrial Fibrillation Substrate. Circulation Research, 2016, 119, 69-82.	2.0	44
168	Visceral Congestion in Heart Failure: Right Ventricular Dysfunction, Splanchnic Hemodynamics, and the Intestinal Microenvironment. Current Heart Failure Reports, 2017, 14, 519-528.	1.3	44
169	Left atrial strain as sensitive marker of left ventricular diastolic dysfunction in heart failure. ESC Heart Failure, 2020, 7, 1956-1965.	1.4	43
170	Selective Serotonin Reuptake Inhibitors and the Incidence and Outcome of Pulmonary Hypertension. Chest, 2009, 136, 694-700.	0.4	42
171	Levosimendan Improves Hemodynamics and Exercise Tolerance in PH-HFpEF. JACC: Heart Failure, 2021, 9, 360-370.	1.9	42
172	Risk assessment in pulmonary hypertension associated with heart failure and preserved ejection fraction. Journal of Heart and Lung Transplantation, 2012, 31, 467-477.	0.3	41
173	Innovative Clinical Trial Designs for Precision Medicine in Heart Failure with Preserved Ejection Fraction. Journal of Cardiovascular Translational Research, 2017, 10, 322-336.	1.1	41
174	Resting and exercise haemodynamics in relation to sixâ€minute walk test in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure, 2018, 20, 715-722.	2.9	41
175	Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction. JAMA Cardiology, 2018, 3, 1000.	3.0	41
176	Diffuse right ventricular fibrosis in heart failure with preserved ejection fraction and pulmonary hypertension. ESC Heart Failure, 2020, 7, 254-264.	1.4	39
177	Differential Associations of ChronicÂInflammatory Diseases With Incident HeartÂFailure. JACC: Heart Failure, 2020, 8, 489-498.	1.9	39
178	Therapeutic Targeting of Left Atrial Myopathy in Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction. JAMA Cardiology, 2020, 5, 497.	3.0	38
179	Relation of Short-Term Heart Rate Variability to Incident Heart Failure (from the Multi-Ethnic Study of) Tj ETQq1 1 0.784314 rgBT /Ove	0.7	37
180	Association of Biomarker Clusters With Cardiac Phenotypes and Mortality in Patients With HIV Infection. Circulation: Heart Failure, 2018, 11, e004312.	1.6	37

#	Article	IF	Citations
181	The Upcoming Epidemic of Heart Failure in South Asia. Circulation: Heart Failure, 2020, 13, e007218.	1.6	37
182	Stepping Out of the Left Ventricleâ€™s Shadow. Circulation: Cardiovascular Imaging, 2017, 10, .	1.3	36
183	Value of Exercise Treadmill Testing in the Risk Stratification of Patients With Pulmonary Hypertension. Circulation: Heart Failure, 2009, 2, 278-286.	1.6	35
184	Polycystic Ovary Syndrome Is Associated with Higher Left Ventricular Mass Index: The CARDIA Women's Study. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 4656-4662.	1.8	35
185	Pulmonary Hypertension Is Associated With a Higher Risk of Heart Failure Hospitalization and Mortality in Patients With Chronic Kidney Disease. Circulation: Heart Failure, 2017, 10, .	1.6	35
186	Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2018, 11, e005288.	1.6	35
187	Venous Tone and Stressed Blood Volume in HeartÂFailure. Journal of the American College of Cardiology, 2022, 79, 1858-1869.	1.2	35
188	Prognostic importance of left ventricular mechanical dyssynchrony in heart failure with preserved ejection fraction. European Journal of Heart Failure, 2017, 19, 1043-1052.	2.9	34
189	Tensor Factorization for Precision Medicine in Heart Failure with Preserved Ejection Fraction. Journal of Cardiovascular Translational Research, 2017, 10, 305-312.	1.1	34
190	Impact of atrial fibrillation on rest and exercise haemodynamics in heart failure with midâ€range and preserved ejection fraction. European Journal of Heart Failure, 2017, 19, 1690-1697.	2.9	34
191	Sex Hormones and Change in N-Terminal Proâ€“B-Type Natriuretic Peptide Levels: The Multi-Ethnic Study of Atherosclerosis. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 4304-4314.	1.8	34
192	Gut Microbial-Related Choline Metabolite Trimethylamine-N-Oxide Is Associated With Progression of Carotid Artery Atherosclerosis in HIV Infection. Journal of Infectious Diseases, 2018, 218, 1474-1479.	1.9	34
193	Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2â€”evidence base and standardized methods of imaging. Journal of Nuclear Cardiology, 2021, 28, 1769-1774.	1.4	34
194	Rationale and Design of the VITALITY-HFpEF Trial. Circulation: Heart Failure, 2019, 12, e005998.	1.6	33
195	Central and Peripheral Determinants of Exercise Capacity in Heart Failure Patients With Preserved Ejection Fraction. JACC: Heart Failure, 2019, 7, 321-332.	1.9	33
196	Cellular Adhesion Molecules in YoungÂAdulthood and Cardiac Function in LaterÂLife. Journal of the American College of Cardiology, 2020, 75, 2156-2165.	1.2	33
197	Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial. ESC Heart Failure, 2020, 7, 856-864.	1.4	33
198	Diastolic Dysfunction in Individuals With Human Immunodeficiency Virus Infection: Literature Review, Rationale and Design of the Characterizing Heart Function on Antiretroviral Therapy (CHART) Study. Journal of Cardiac Failure, 2018, 24, 255-265.	0.7	32

#	Article	IF	Citations
199	Transcatheter InterAtrial Shunt Device for the treatment of heart failure: Rationale and design of the pivotal randomized trial to REDUCE Elevated Left Atrial Pressure in Patients with Heart Failure II (REDUCE LAP-HF II). American Heart Journal, 2020, 226, 222-231.	1.2	32
200	Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction. Canadian Journal of Cardiology, 2015, 31, 430-439.	0.8	31
201	Rationale and Design of the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (Reduce LAP-HF) Trial. Journal of Cardiac Failure, 2015, 21, 594-600.	0.7	31
202	Association of Chronic Kidney Disease With Chronotropic Incompetence in Heart Failure With Preserved EjectionÂFraction. American Journal of Cardiology, 2015, 116, 1093-1100.	0.7	31
203	Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure Trial. Circulation: Heart Failure, 2018, 11, e004457.	1.6	31
204	Disproportionate left atrial myopathy in heart failure with preserved ejection fraction among participants of the PROMIS-HFpEF study. Scientific Reports, 2021, 11, 4885.	1.6	31
205	Increased Arterial Wave Reflection Magnitude. Journal of the American College of Cardiology, 2012, 60, 2178-2181.	1.2	30
206	Treatment of Heart Failure With Preserved Ejection Fraction (HFpEF): the Phenotype-Guided Approach. Current Treatment Options in Cardiovascular Medicine, 2019, 21, 20.	0.4	30
207	Elevated Plasma Ceramides Are Associated With Antiretroviral Therapy Use and Progression of Carotid Artery Atherosclerosis in HIV Infection. Circulation, 2019, 139, 2003-2011.	1.6	30
208	Circulating Vascular Cell Adhesion Moleculeâ€1 and Incident Heart Failure: The Multiâ€Ethnic Study of Atherosclerosis (MESA). Journal of the American Heart Association, 2020, 9, e019390.	1.6	30
209	Acute Myocardial Infarction in Patients With Versus Without Aortic Valve Sclerosis and Effect of Statin Therapy (from the Heart and Soul Study). American Journal of Cardiology, 2007, 99, 1128-1133.	0.7	29
210	Association of the Frontal QRS-T Angle with Adverse Cardiac Remodeling, Impaired Left and Right Ventricular Function, and Worse Outcomes in Heart Failure with Preserved Ejection Fraction. Journal of the American Society of Echocardiography, 2014, 27, 74-82.e2.	1.2	29
211	Association of Impaired Glucose Regulation and Insulin Resistance With Cardiac Structure and Function. Circulation: Cardiovascular Imaging, 2016, 9, .	1.3	29
212	Association of Coronary Microvascular Dysfunction With Heart Failure Hospitalizations and Mortality in Heart Failure With Preserved Ejection Fraction: A Follow-up in the PROMIS-HFpEF Study. Journal of Cardiac Failure, 2020, 26, 1016-1021.	0.7	29
213	Prognostic Value of Minimal Left Atrial Volume in Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association, 2021, 10, e019545.	1.6	29
214	Associations of Macro- and Microvascular Endothelial Dysfunction With Subclinical Ventricular Dysfunction in End-Stage Renal Disease. Hypertension, 2016, 68, 913-920.	1.3	28
215	Inflammation in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure, 2016, 4, 325-328.	1.9	28
216	Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trial. European Journal of Heart Failure, 2018, 20, 483-490.	2.9	28

#	Article	IF	Citations
217	Cystic fibrosis transmembrane conductance regulator in human and mouse red blood cell membranes and its interaction with ecto-apyrase. Journal of Cellular Biochemistry, 2004, 91, 1174-1182.	1.2	27
218	Evolving Approaches to the Management of Heart Failure with Preserved Ejection Fraction in Patients with Coronary Artery Disease. Current Treatment Options in Cardiovascular Medicine, 2010, 12, 58-75.	0.4	27
219	Timeâ€resolved magnetic resonance angiography: Evaluation of intrapulmonary circulation parameters in pulmonary arterial hypertension. Journal of Magnetic Resonance Imaging, 2011, 33, 225-231.	1.9	27
220	Association of 6â€Minute Walk Performance and Physical Activity With Incident Ischemic Heart Disease Events and Stroke in Peripheral Artery Disease. Journal of the American Heart Association, 2015, 4, .	1.6	27
221	How to Develop and Implement a Specialized Heart Failure with Preserved Ejection Fraction Clinical Program. Current Cardiology Reports, 2016, 18, 122.	1.3	27
222	Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1â€receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction. European Journal of Heart Failure, 2018, 20, 1601-1610.	2.9	27
223	Immunometabolic mechanisms of heart failure with preserved ejection fraction. , 2022, 1, 211-222.		27
224	Endovascular ablation of the right greater splanchnic nerve in heart failure with preserved ejection fraction: early results of the <scp>REBALANCEâ€HF</scp> trial rollâ€in cohort. European Journal of Heart Failure, 2022, 24, 1410-1414.	2.9	27
225	Sudden cardiac death in heart failure with preserved ejection fraction: a target for therapy?. Heart Failure Reviews, 2016, 21, 455-462.	1.7	26
226	Association of Lipidomic Profiles With Progression of Carotid Artery Atherosclerosis in HIV Infection. JAMA Cardiology, 2019, 4, 1239.	3.0	26
227	Adverse Renal Response to Decongestion in the Obese Phenotype of Heart Failure With Preserved Ejection Fraction. Journal of Cardiac Failure, 2020, 26, 101-107.	0.7	26
228	Pulse Pressure, Prognosis, and Influence of Sacubitril/Valsartan in Heart Failure With Preserved Ejection Fraction. Hypertension, 2021, 77, 546-556.	1.3	26
229	Inhibition of the late sodium current slows t-tubule disruption during the progression of hypertensive heart disease in the rat. American Journal of Physiology - Heart and Circulatory Physiology, 2013, 305, H1068-H1079.	1.5	25
230	Combined post- and pre-capillary pulmonary hypertension in heart failure with preserved ejection fraction. Heart Failure Reviews, 2016, 21, 285-297.	1.7	25
231	Clinical characteristics of HIV-infected patients with adjudicated heart failure. European Journal of Preventive Cardiology, 2017, 24, 1746-1758.	0.8	25
232	Diastolic Dysfunction in Patients With Human Immunodeficiency Virus Receiving Antiretroviral Therapy: Results From the CHART Study. Journal of Cardiac Failure, 2020, 26, 371-380.	0.7	25
233	Cardiac safe hematopoietic stem cell transplantation for systemic sclerosis with poor cardiac function: a pilot safety study that decreases neutropenic interval to 5 days. Bone Marrow Transplantation, 2021, 56, 50-59.	1.3	25
234	Clinical Characteristics and Outcomes of Adults With a History of Heart Failure Hospitalized for COVID-19. Circulation: Heart Failure, 2021, 14, e008354.	1.6	25

#	Article	IF	Citations
235	Hemodynamic Correlates of the Third Heart Sound and Systolic Time Intervals. Congestive Heart Failure, 2006, 12, 8-13.	2.0	24
236	A candidate gene study reveals association between a variant of the Peroxisome Proliferator-Activated Receptor Gamma (PPAR-Î³) gene and systemic sclerosis. Arthritis Research and Therapy, 2015, 17, 128.	1.6	24
237	Archeological Echocardiography: Digitization and Speckle Tracking Analysis of Archival Echocardiograms in the Hyper<scp>GEN</scp> Study. Echocardiography, 2016, 33, 386-397.	0.3	24
238	Reduced haemodynamic coupling and exercise are associated with vascular stiffening in pulmonary arterial hypertension. Heart, 2017, 103, 421-427.	1.2	24
239	Evaluation of highâ€sensitivity Câ€reactive protein and uric acid in vericiguatâ€treated patients with heart failure with reduced ejection fraction. European Journal of Heart Failure, 2020, 22, 1675-1683.	2.9	24
240	Association of the Fourth Heart Sound With Increased Left Ventricular End-Diastolic Stiffness. Journal of Cardiac Failure, 2008, 14, 431-436.	0.7	23
241	Hematopoietic Stem Cell Transplantation for Systemic Sclerosis: If You Are Confused, Remember: â€œIt Is a Matter of the Heartâ€. Journal of Rheumatology, 2012, 39, 206-209.	1.0	23
242	Current Perspectives on Systemic Hypertension in Heart Failure with Preserved Ejection Fraction. Current Cardiology Reports, 2014, 16, 545.	1.3	23
243	GWAS of the electrocardiographic QT interval in Hispanics/Latinos generalizes previously identified loci and identifies population-specific signals. Scientific Reports, 2017, 7, 17075.	1.6	23
244	Impact of Baseline Hemodynamics on the Effects of a Transcatheter Interatrial Shunt Device in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2018, 11, e004540.	1.6	23
245	Baseline Longitudinal Strain Predicts Recovery of Left Ventricular Ejection Fraction in Hospitalized Patients With Nonischemic Cardiomyopathy. Journal of the American Heart Association, 2018, 7, e09841.	1.6	23
246	Drug Targets for Heart Failure with Preserved Ejection Fraction: A Mechanistic Approach and Review of Contemporary Clinical Trials. Annual Review of Pharmacology and Toxicology, 2019, 59, 41-63.	4.2	23
247	Brief Report: Association of Elevated Adipsin Levels With Pulmonary Arterial Hypertension in Systemic Sclerosis. Arthritis and Rheumatology, 2017, 69, 2062-2068.	2.9	22
248	Relation of Sex Hormone Levels With Prevalent and 10-Year Change in Aortic Distensibility Assessed by MRI: The Multi-Ethnic Study of Atherosclerosis. American Journal of Hypertension, 2018, 31, 774-783.	1.0	22
249	Diffuse cardiac fibrosis quantification in early systemic sclerosis by magnetic resonance imaging and correlation with skin fibrosis. Journal of Scleroderma and Related Disorders, 2018, 3, 159-169.	1.0	22
250	Characterization of cardiac mechanics and incident atrial fibrillation in participants of the Cardiovascular Health Study. JCI Insight, 2020, 5, .	2.3	22
251	Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update. Orphanet Journal of Rare Diseases, 2022, 17, .	1.2	22
252	Combining patient proteomics and in vitro cardiomyocyte phenotype testing to identify potential mediators of heart failure with preserved ejection fraction. Journal of Translational Medicine, 2016, 14, 18.	1.8	21

#	Article	IF	Citations
253	Community walking speed, sedentary or lying down time, and mortality in peripheral artery disease. Vascular Medicine, 2016, 21, 120-129.	0.8	21
254	Prevalence and Predictors of Diastolic Dysfunction According to Different Classification Criteria. American Journal of Epidemiology, 2017, 185, 1221-1227.	1.6	21
255	Prognostic Importance of Temporal Changes in Resting Heart Rate in Heart Failure and Preserved Ejection Fraction. JACC: Heart Failure, 2017, 5, 782-791.	1.9	21
256	Association of Estimated SodiumÂIntakeÂWith Adverse Cardiac Structure andÂFunction. Journal of the American College of Cardiology, 2017, 70, 715-724.	1.2	21
257	Utility of the Cardiovascular Physical Examination and Impact of Spironolactone in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2019, 12, e006125.	1.6	21
258	Fibroblast Growth Factor 23 and Long-Term Cardiac Function. Circulation: Cardiovascular Imaging, 2020, 13, e011925.	1.3	21
259	Diagnostic and prognostic implications of heart failure with preserved ejection fraction scoring systems. ESC Heart Failure, 2021, 8, 2089-2102.	1.4	21
260	Visceral adiposity, muscle composition, and exercise tolerance in heart failure with preserved ejection fraction. ESC Heart Failure, 2021, 8, 2535-2545.	1.4	21
261	Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey. JACC: CardioOncology, 2021, 3, 537-546.	1.7	21
262	MDCT Bolus Tracking Data as an Adjunct for Predicting the Diagnosis of Pulmonary Hypertension and Concomitant Right-Heart Failure. American Journal of Roentgenology, 2011, 197, 1064-1072.	1.0	20
263	A contemporary analysis of pulmonary hypertension in patients undergoing mitral valve surgery: Is this a risk factor?. Journal of Thoracic and Cardiovascular Surgery, 2016, 151, 1288-1299.	0.4	20
264	Impact of the Gather mHealth System on A1C: Primary Results of a Multisite Randomized Clinical Trial Among People With Type 2 Diabetes in India. Diabetes Care, 2016, 39, e169-e170.	4.3	20
265	HIV-Related Myocardial Vulnerability to Infarction and Coronary Artery Disease. Journal of the American College of Cardiology, 2016, 68, 2026-2027.	1.2	20
266	Comparison of Echocardiographic Measures in a Hispanic/Latino Population With the 2005 and 2015 American Society of Echocardiography Reference Limits (The Echocardiographic Study of Latinos). Circulation: Cardiovascular Imaging, 2016, 9, .	1.3	20
267	Right Ventricular Structure and Function Are Associated With Incident Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2017, 10, .	2.1	20
268	Advances in the pharmacotherapy of chronic heart failure with preserved ejection fraction: an ideal opportunity for precision medicine. Expert Opinion on Pharmacotherapy, 2017, 18, 399-409.	0.9	20
269	Parent-of-origin effects on quantitative phenotypes in a large Hutterite pedigree. Communications Biology, 2019, 2, 28.	2.0	20
270	Application of machine learning to determine top predictors of noncalcified coronary burden in psoriasis: An observational cohort study. Journal of the American Academy of Dermatology, 2020, 83, 1647-1653.	0.6	20

#	Article	IF	Citations
271	Generalizability of HFA-PEFF and H2FPEF Diagnostic Algorithms and Associations With Heart Failure Indices and Proteomic Biomarkers: Insights From PROMIS-HFpEF. Journal of Cardiac Failure, 2021, 27, 756-765.	0.7	20
272	BNP: Biomarker Not Perfect in heart failure with preserved ejection fraction. European Heart Journal, 2022, 43, 1952-1954.	1.0	20
273	Physiology of the Third Heart Sound: Novel Insights from Tissue Doppler Imaging. Journal of the American Society of Echocardiography, 2008, 21, 394-400.	1.2	19
274	Association of Comorbidity Burden With Abnormal Cardiac Mechanics: Findings From the HyperGEN Study. Journal of the American Heart Association, 2014, 3, e000631.	1.6	19
275	Fine mapping of QT interval regions in global populations refines previously identified QT interval loci and identifies signals unique to African and Hispanic descent populations. Heart Rhythm, 2017, 14, 572-580.	0.3	19
276	Prevalence of American Heart Association Heart Failure Stages in Black and White Young and Middle-Aged Adults. Circulation: Heart Failure, 2019, 12, e005730.	1.6	19
277	The role of splanchnic congestion and the intestinal microenvironment in the pathogenesis of advanced heart failure. Current Opinion in Supportive and Palliative Care, 2019, 13, 24-30.	0.5	19
278	Impact of Interatrial Shunts on Invasive Hemodynamics and Exercise Tolerance in Patients With Heart Failure. Journal of the American Heart Association, 2020, 9, e016760.	1.6	19
279	Predicting High-Risk Patients and High-Risk Outcomes in Heart Failure. Heart Failure Clinics, 2020, 16, 387-407.	1.0	19
280	Risk-Based Approach for the Prediction and Prevention of Heart Failure. Circulation: Heart Failure, 2021, 14, e007761.	1.6	19
281	Spironolactone in Patients With HeartÂFailure, Preserved Ejection Fraction, and Worsening Renal Function. Journal of the American College of Cardiology, 2021, 77, 1211-1221.	1.2	19
282	Determinants and consequences of heart rate and stroke volume response to exercise in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure, 2021, 23, 754-764.	2.9	19
283	Left Atrial Myopathy in Atrial Fibrillation and Heart Failure: Clinical Implications, Mechanisms, and Therapeutic Targets. Current Heart Failure Reports, 2021, 18, 85-98.	1.3	19
284	Relationship between repolarization heterogeneity and abnormal myocardial mechanics. International Journal of Cardiology, 2014, 172, 289-291.	0.8	18
285	Integrated analyses of gene expression and genetic association studies in a founder population. Human Molecular Genetics, 2016, 25, 2104-2112.	1.4	18
286	Application of the H₂FPEF score to a global clinical trial of patients with heart failure with preserved ejection fraction: the TOPCAT trial. European Journal of Heart Failure, 2019, 21, 1288-1291.	2.9	18
287	Association of Longitudinal Trajectory of Albuminuria in Young Adulthood With Myocardial Structure and Function in Later Life. JAMA Cardiology, 2020, 5, 184.	3.0	18
288	Association of Hyper-Polypharmacy With Clinical Outcomes in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2021, 14, e008293.	1.6	18

#	Article	IF	Citations
289	Atrial Fibrillation in HeartÂFailure With Preserved Ejection Fraction. JACC: Heart Failure, 2022, 10, 336-346.	1.9	18
290	Changes in D-dimer and inflammatory biomarkers before ischemic events in patients with peripheral artery disease: The BRAVO Study. Vascular Medicine, 2016, 21, 12-20.	0.8	17
291	Associations Between the Cyclic Guanosine Monophosphate Pathway and Cardiovascular Risk Factors: MESA. Journal of the American Heart Association, 2019, 8, e013149.	1.6	17
292	Predictive Accuracy of Heart Failure-Specific Risk Equations in an Electronic Health Record-Based Cohort. Circulation: Heart Failure, 2020, 13, e007462.	1.6	17
293	Myocardial Infarction in HeartÂFailure With Preserved Ejection Fraction. JACC: Heart Failure, 2020, 8, 618-626.	1.9	17
294	Spironolactone in Patients With an Echocardiographic HFpEF Phenotype Suggestive of Cardiac Amyloidosis. JACC: Heart Failure, 2021, 9, 795-802.	1.9	17
295	Initiation and Gradual Intensification of Premixed Insulin Lispro Therapy Versus Basal Â± Mealtime Insulin in Patients With Type 2 Diabetes Eating Light Breakfasts. Diabetes Care, 2014, 37, 372-380.	4.3	16
296	Biomarker Correlates of Coronary Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction. Circulation, 2019, 140, 1359-1361.	1.6	16
297	Coronary Microvascular Dysfunction in HIV: A Review. Journal of the American Heart Association, 2020, 9, e014018.	1.6	16
298	Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program. ESC Heart Failure, 2021, 8, 1482-1493.	1.4	16
299	Heart Failure Risk Distribution and Trends in the United States Population, NHANES 1999-2016. American Journal of Medicine, 2021, 134, e153-e164.	0.6	16
300	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2â€"Diagnostic Criteria and Appropriate Utilization. Circulation: Cardiovascular Imaging, 2021, 14, e000030.	1.3	16
301	Sex differences in proteomic correlates of coronary microvascular dysfunction among patients with heart failure and preserved ejection fraction. European Journal of Heart Failure, 2022, 24, 681-684.	2.9	16
302	Spironolactone for Management of Heart Failure with Preserved Ejection Fraction: Whither to After TOPCAT?. Current Atherosclerosis Reports, 2015, 17, 64.	2.0	15
303	A non-invasive assessment of cardiopulmonary hemodynamics with MRI in pulmonary hypertension. Magnetic Resonance Imaging, 2015, 33, 1224-1235.	1.0	15
304	Differences in Repolarization Heterogeneity Among Heart Failure With Preserved Ejection Fraction Phenotypic Subgroups. American Journal of Cardiology, 2017, 120, 601-606.	0.7	15
305	20th Annual Feigenbaum Lecture: Echocardiography for Precision Medicineâ€"Digital Biopsy to Deconstruct Biology. Journal of the American Society of Echocardiography, 2019, 32, 1379-1395.e2.	1.2	15
306	Polygenic Risk, Fitness, and Obesity in the Coronary Artery Risk Development in Young Adults (CARDIA) Study. JAMA Cardiology, 2020, 5, 263.	3.0	15

#	Article	IF	Citations
307	Preoperative left atrial strain abnormalities are associated with the development of postoperative atrial fibrillation following isolated coronary artery bypass surgery. Journal of Thoracic and Cardiovascular Surgery, 2022, 164, 917-924.	0.4	15
308	Challenges of Cardio-Kidney Composite Outcomes in Large-Scale Clinical Trials. Circulation, 2021, 143, 949-958.	1.6	15
309	Rationale and Design of the Echocardiographic Study of Hispanics/Latinos (ECHO-SOL). Ethnicity and Disease, 2015, 25, 180-6.	1.0	15
310	Hemodynamic Correlates of the Third Heart Sound and Systolic Time Intervals. Congestive Heart Failure, 2006, 12, 8-13.	2.0	14
311	Diastolic wall strain: a simple marker of abnormal cardiac mechanics. Cardiovascular Ultrasound, 2014, 12, 40.	0.5	14
312	Association of the von Willebrand Factorâ€“ADAMTS13 Ratio With Incident Cardiovascular Events in Patients With Peripheral Arterial Disease. Clinical and Applied Thrombosis/Hemostasis, 2017, 23, 807-813.	0.7	14
313	Reassessing Phase II Heart Failure Clinical Trials. Circulation: Heart Failure, 2017, 10, .	1.6	14
314	Sex differences in vascular dysfunction and cardiovascular outcomes: The cardiac, endothelial function, and arterial stiffness in ESRD (CERES) study. Hemodialysis International, 2018, 22, 93-102.	0.4	14
315	Coronary Microvascular Dysfunction and Clinical Outcomes in Patients With Heart Failure With Preserved Ejection Fraction. Journal of Cardiac Failure, 2019, 25, 843-845.	0.7	14
316	Associations of awake and asleep blood pressure and blood pressure dipping with abnormalities of cardiac structure. Journal of Hypertension, 2020, 38, 102-110.	0.3	14
317	Rationale and design for a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart failure with preserved ejection fraction (CAPACITY HFpEF). American Heart Journal, 2020, 222, 183-190.	1.2	14
318	Cyclic Guanosine Monophosphate and Risk of Incident Heart Failure and Other Cardiovascular Events: the ARIC Study. Journal of the American Heart Association, 2020, 9, e013966.	1.6	14
319	Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials. Cardiovascular Diabetology, 2022, 21, .	2.7	14
320	Phase II trials in heart failure: The role of cardiovascular imaging. American Heart Journal, 2011, 162, 3-15.e3.	1.2	13
321	Designing Future Clinical Trials in Heart Failure With Preserved Ejection Fraction: Lessons From TOPCAT. Current Heart Failure Reports, 2017, 14, 217-222.	1.3	13
322	Pulmonary artery to aorta ratio is associated with cardiac structure and functional changes in mild-to-moderate COPD. International Journal of COPD, 2017, Volume 12, 1439-1446.	0.9	13
323	Teasing Apart Heart Failure With Preserved Ejection Fraction Phenotypes With Echocardiographic Imaging. Circulation Research, 2018, 122, 23-25.	2.0	13
324	Association of Patterns of Change in Adiposity With Diastolic Function and Systolic Myocardial Mechanics From Early Adulthood to Middle Age: The Coronary Artery Risk Development in Young Adults Study. Journal of the American Society of Echocardiography, 2018, 31, 1261-1269.e8.	1.2	13

#	Article	IF	Citations
325	Assessment of Predictors of Left Atrial Volume Response to a Transcatheter InterAtrial Shunt Device (from the REDUCE LAP-HF Trial). American Journal of Cardiology, 2019, 124, 1912-1917.	0.7	13
326	Right Ventricular and Pulmonary Vascular Function are Influenced by Age and Volume Expansion in Healthy Humans. Journal of Cardiac Failure, 2019, 25, 51-59.	0.7	13
327	Associations of Cardiac Mechanics With Exercise Capacity. Journal of the American College of Cardiology, 2021, 78, 245-257.	1.2	13
328	Understanding the Pathobiology of Pulmonary Hypertension Due to Left Heart Disease. Circulation Research, 2022, 130, 1382-1403.	2.0	13
329	Integrating hypertension phenotype and genotype with hybrid non-negative matrix factorization. Bioinformatics, 2019, 35, 1395-1403.	1.8	12
330	Serum potassium and outcomes in heart failure with preserved ejection fraction: a postâ€hoc analysis of the <scp>PARAGONâ€HF</scp> trial. European Journal of Heart Failure, 2021, 23, 776-784.	2.9	12
331	Baseline characteristics of patients in the PARALLAX trial: insights into quality of life and exercise capacity in heart failure with preserved ejection fraction. European Journal of Heart Failure, 2021, 23, 1541-1551.	2.9	12
332	Cardiac mechanics and incident ischemic stroke: the Cardiovascular Health Study. Scientific Reports, 2021, 11, 17358.	1.6	12
333	Lung function impairment and risk of incident heart failure: the NHLBI Pooled Cohorts Study. European Heart Journal, 2022, 43, 2196-2208.	1.0	12
334	The future of heart failure with preserved ejection fraction. Herz, 2022, 47, 308-323.	0.4	12
335	Normalization of Ejection Fraction and Resolution of Symptoms in Chronic Severe Heart Failure is Possible With Modern Medical Therapy: Clinical Observations in 11 Patients. American Journal of Therapeutics, 2008, 15, 206-213.	0.5	11
336	Cardiac Assessment Before Stem Cell Transplantation for Systemic Sclerosis. JAMA - Journal of the American Medical Association, 2014, 312, 1803.	3.8	11
337	Vulnerable blood in high risk vascular patients: Study design and methods. Contemporary Clinical Trials, 2014, 38, 121-129.	0.8	11
338	Soluble Guanylate Cyclase Stimulators: a Novel Treatment Option for Heart Failure Associated with Cardiorenal Syndromes?. Current Heart Failure Reports, 2016, 13, 132-139.	1.3	11
339	Albuminuria, kidney function, and sudden cardiac death: Findings from The Reasons for Geographic and Racial Differences in Stroke (REGARDS) study. Heart Rhythm, 2017, 14, 65-71.	0.3	11
340	Variation in clinical and patientâ€reported outcomes among complex heart failure with preserved ejection fraction phenotypes. ESC Heart Failure, 2020, 7, 811-824.	1.4	11
341	Burden of HeartÂFailure Signs and Symptoms, Prognosis, and ResponseÂtoÂTherapy. JACC: Heart Failure, 2021, 9, 386-397.	1.9	11
342	Changes in Stressed Blood Volume with Levosimendan in Pulmonary Hypertension from Heart Failure with Preserved Ejection Fraction: Insights Regarding Mechanism of Action From the HELP Trial. Journal of Cardiac Failure, 2021, 27, 1023-1026.	0.7	11

#	Article	IF	Citations
343	SERCA2a Gene Therapy for the Prevention of Sudden Cardiac Death. Circulation, 2012, 126, 2047-2050.	1.6	10
344	Consensus guidelines for glycemic monitoring in type 1/type 2 & GDM. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2014, 8, 187-195.	1.8	10
345	Role of Angiotensin Receptor-Neprilysin Inhibition in Heart Failure. Current Atherosclerosis Reports, 2016, 18, 48.	2.0	10
346	Endothelial nitric oxide synthase genotype is associated with pulmonary hypertension severity in left heart failure patients. Pulmonary Circulation, 2018, 8, 1-8.	0.8	10
347	History of Atrial Fibrillation and Trajectory of Decongestion in AcuteÂHeart Failure. JACC: Heart Failure, 2019, 7, 47-55.	1.9	10
348	Association of liver stiffness and cardiovascular outcomes in patients with heart failure: A systematic review and meta-analysis. European Journal of Preventive Cardiology, 2020, 27, 331-334.	0.8	10
349	Biomarker Profile of Left Atrial Myopathy in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial. Journal of Cardiac Failure, 2020, 26, 270-275.	0.7	10
350	Characterization of the Progression From Ambulatory to Hospitalized Heart Failure With Preserved Ejection Fraction. Journal of Cardiac Failure, 2020, 26, 919-928.	0.7	10
351	A Prospective Pilot Study of Pocket-Carried Ultrasound Pre- and Postdischarge Inferior Vena Cava Assessment for Prediction of Heart Failure Rehospitalization. Journal of Cardiac Failure, 2018, 24, 614-617.	0.7	9
352	Leucocyte count predicts cardiovascular risk in heart failure with preserved ejection fraction: insights from TOPCAT Americas. ESC Heart Failure, 2020, 7, 1676-1687.	1.4	9
353	Renal Dysfunction in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial. Journal of Cardiac Failure, 2020, 26, 233-242.	0.7	9
354	Fibroblast Growth Factor 23 and Exercise Capacity in Heart Failure with Preserved Ejection Fraction. Journal of Cardiac Failure, 2021, 27, 309-317.	0.7	9
355	Interventional heart failure: a new field. EuroIntervention, 2016, 12, X85-X88.	1.4	9
356	Development and Validation of a Long-Term Incident Heart Failure Risk Model. Circulation Research, 2022, 130, 200-209.	2.0	9
357	Transthyretin V142I Genetic Variant and Cardiac Remodeling, Injury, and HeartÂFailure Risk in Black Adults. JACC: Heart Failure, 2022, 10, 129-138.	1.9	9
358	Advances in Machine Learning Approaches to Heart Failure with Preserved Ejection Fraction. Heart Failure Clinics, 2022, 18, 287-300.	1.0	9
359	Has acetylcysteine use changed the incidence of contrast nephropathy in hospitalized patients? A before-after study. American Journal of Medicine, 2004, 117, 948-952.	0.6	8
360	Nesiritide: a reappraisal of efficacy and safety. Expert Opinion on Pharmacotherapy, 2007, 8, 361-369.	0.9	8

#	Article	IF	Citations
361	Evaluative Framework for Phase II Studies in Patients With Heart Failure and Preserved Ejection Fraction. JACC: Heart Failure, 2013, 1, 123-126.	1.9	8
362	Microvascular dysfunction and cardiac fibrosis in heart failure with preserved ejection fraction: a case report. ESC Heart Failure, 2017, 4, 645-648.	1.4	8
363	Ankleâ€“brachial index and incident heart failure with reduced versus preserved ejection fraction: The Multi-Ethnic Study of Atherosclerosis. Vascular Medicine, 2019, 24, 501-510.	0.8	8
364	Effect of canagliflozin use on body weight and blood pressure at one-year follow-up: A systematic review and meta-analysis. European Journal of Preventive Cardiology, 2019, 26, 1680-1682.	0.8	8
365	Real-Life Multimarker Monitoring in Patients with Heart Failure: Continuous Remote Monitoring of Mobility and Patient-Reported Outcomes as Digital End Points in Future Heart-Failure Trials. Digital Biomarkers, 2020, 4, 45-59.	2.2	8
366	Go Red for Women Strategically Focused Research Network: Summary of Findings and Network Outcomes. Journal of the American Heart Association, 2021, 10, e019519.	1.6	8
367	Identification of Cardiac Fibrosis in Young Adults With a Homozygous Frameshift Variant in SERPINE1. JAMA Cardiology, 2021, 6, 841.	3.0	8
368	Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2â€"Evidence Base and Standardized Methods of Imaging. Journal of Cardiac Failure, 2022, 28, e1-e4.	0.7	8
369	Left atrial strain is associated with adverse cardiovascular events in patients with endâ€stage renal disease: Findings from the Cardiac, Endothelial Function and Arterial Stiffness in <scp>ESRD</scp> (<scp>CERES</scp>) study. Hemodialysis International, 2022, 26, 323-334.	0.4	8
370	Favorable levels of all major cardiovascular risk factors at younger ages and high-sensitivity C-reactive protein 39years later â€" The Chicago Healthy Aging Study. Preventive Medicine Reports, 2015, 2, 235-240.	0.8	7
371	Sedentary Lifestyle and the Risk for HFpEF. Journal of the American College of Cardiology, 2017, 69, 1143-1146.	1.2	7
372	Targeted Therapeutics for Transthyretin Cardiac Amyloidosis. Circulation, 2019, 139, 444-447.	1.6	7
373	Association of the V122I Transthyretin Amyloidosis Genetic Variant With Cardiac Structure and Function in Middle-aged Black Adults. JAMA Cardiology, 2021, 6, 718.	3.0	7
374	Transmethylamineâ€Nâ€Oxide Is Associated With Diffuse Cardiac Fibrosis in People Living With HIV. Journal of the American Heart Association, 2021, 10, e020499.	1.6	7
375	Risk Markers for Limited Coronary Artery Calcium in Persons With Significant Aortic Valve Calcium (From the Multi-ethnic Study of Atherosclerosis). American Journal of Cardiology, 2021, 156, 58-64.	0.7	7
376	Risk-Based Intensive Blood Pressure Lowering and Prevention of Heart Failure: A SPRINT Post Hoc Analysis. Hypertension, 2021, 78, 1742-1749.	1.3	7
377	Limitations Inherent to the Simplified Bernoulli Equation Explain the Inaccuracy of Doppler Echocardiographic Estimates of Pulmonary Artery Pressures in Patients With Pulmonary Hypertension: Response. Chest, 2011, 140, 270-271.	0.4	6
378	Generation of human iPSCs from urine derived cells of patient with a novel heterozygous PAI-1 mutation. Stem Cell Research, 2017, 18, 41-44.	0.3	6

#	Article	IF	Citations
379	Generation of human iPSCs from urine derived cells of a non-affected control subject. Stem Cell Research, 2017, 18, 33-36.	0.3	6
380	Association of Albuminuria With Cardiac Dysfunction in US Hispanics/Latinos. American Journal of Cardiology, 2017, 119, 2073-2080.	0.7	6
381	Lack of Association Between Anemia and Intrinsic Left Ventricular Diastolic Function or Cardiac Mechanics in Heart Failure With Preserved Ejection Fraction. American Journal of Cardiology, 2018, 122, 1359-1365.	0.7	6
382	Influence of Age on Efficacy and Safety ofÂSpironolactone in HeartÂFailure. JACC: Heart Failure, 2019, 7, 1022-1028.	1.9	6
383	Relation of Biomarkers of Cardiac Injury, Stress, and Fibrosis With Cardiac Mechanics in Patients â‰¥ 65 Years of Age. American Journal of Cardiology, 2020, 136, 156-163.	0.7	6
384	Association of Midlife Cardiovascular Risk Factors With the Risk of Heart Failure Subtypes Later in Life. Journal of Cardiac Failure, 2021, 27, 435-444.	0.7	6
385	Role of t-tubule remodeling on mechanisms of abnormal calcium release during heart failure development in canine ventricle. American Journal of Physiology - Heart and Circulatory Physiology, 2021, 320, H1658-H1669.	1.5	6
386	Adverse cardiac mechanics and incident coronary heart disease in the Cardiovascular Health Study. Heart, 2022, 108, 529-535.	1.2	6
387	Relation of Cigarette Smoking and Heart Failure in Adults â‰¥65ÂYears of Age (From the Cardiovascular) Tj ETQq1 1 0.784314 rgBT	0.7	6
388	Rare Genetic Variants Associated With Myocardial Fibrosis: Multi-Ethnic Study of Atherosclerosis. Frontiers in Cardiovascular Medicine, 2022, 9, 804788.	1.1	6
389	Genetics of systemic sclerosis-associated pulmonary arterial hypertension: Recent progress and current concepts. Current Rheumatology Reports, 2009, 11, 89-96.	2.1	5
390	Acute Effects of Intravenous Nesiritide on Cardiac Contractility in Heart Failure. Journal of Cardiac Failure, 2010, 16, 720-727.	0.7	5
391	Constrictive Pericarditis as a Cause of Refractory Ascites. ACG Case Reports Journal, 2015, 2, 175-177.	0.2	5
392	Pedal Edema as an Indicator of Early Heart Failure in the Community. Circulation: Heart Failure, 2016, 9, .	1.6	5
393	Influence of ejection fraction on causeâ€specific mortality in heart failure with preserved ejection fraction. European Journal of Heart Failure, 2018, 20, 815-816.	2.9	5
394	The Urgent Need for Biomarkers Beyond B-Type Natriuretic Peptide for the Diagnosis and Management of Heart Failure With Preserved Ejection Fraction. JAMA Cardiology, 2018, 3, 1211.	3.0	5
395	Clinical correlates and heritability of cardiac mechanics: The HyperGEN study. International Journal of Cardiology, 2019, 274, 208-213.	0.8	5
396	Physical Activity, Quality of Life, and Biomarkers in Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction (from the NEAT-HFpEF Trial). American Journal of Cardiology, 2019, 123, 1660-1666.	0.7	5

#	Article	IF	Citations
397	Impact of pulmonary disease on the prognosis in heart failure with preserved ejection fraction: the TOPCAT trial. European Journal of Heart Failure, 2020, 22, 557-559.	2.9	5
398	Genetic-Based Hypertension Subtype Identification Using Informative SNPs. Genes, 2020, 11, 1265.	1.0	5
399	Could a Low-Dose Diuretic Polypill Improve Outcomes in Heart Failure With Preserved Ejection Fraction?. Circulation: Heart Failure, 2021, 14, e008090.	1.6	5
400	Application of Guideline-Based Echocardiographic Assessment of Left Atrial Pressure to Heart Failure with Preserved Ejection Fraction. Journal of the American Society of Echocardiography, 2021, 34, 455-464.	1.2	5
401	Association Between Myocardial Strain and Frailty in CHS. Circulation: Cardiovascular Imaging, 2021, 14, e012116.	1.3	5
402	Associations of body size and composition with subclinical cardiac dysfunction in older individuals: the cardiovascular health study. International Journal of Obesity, 2021, 45, 2539-2545.	1.6	5
403	Genomeâ€wide metaâ€analysis of SNP and antihypertensive medication interactions on left ventricular traits in African Americans. Molecular Genetics & Genomic Medicine, 2019, 7, e00788.	0.6	4
404	Racial Differences and Temporal Obesity Trends in Heart Failure with Preserved Ejection Fraction. Journal of the American Geriatrics Society, 2021, 69, 1309-1318.	1.3	4
405	Antihypertensive Class and Cardiovascular Outcomes in Patients With HIV and Hypertension. Hypertension, 2021, 77, 2023-2033.	1.3	4
406	Association of immune cell subsets with cardiac mechanics in the Multi-Ethnic Study of Atherosclerosis. JCI Insight, 2021, 6, .	2.3	4
407	Systematic examination of a heart failure risk prediction tool: The pooled cohort equations to prevent heart failure. PLoS ONE, 2020, 15, e0240567.	1.1	4
408	Association of the H₂FPEF Risk Score with Recurrence of Atrial Fibrillation Following Pulmonary Vein Isolation. Journal of Atrial Fibrillation, 2020, 12, 2295.	0.5	4
409	The association between indices of blood pressure waveforms (PTC1 and PTC2) and incident heart failure. Journal of Hypertension, 2021, 39, 661-666.	0.3	4
410	Electrocardiographic Markers of Repolarization Heterogeneity During Dofetilide or Sotalol Initiation for Paroxysmal Atrial Fibrillation. American Journal of Cardiology, 2014, 113, 2030-2035.	0.7	3
411	Generation of human iPSCs from urine derived cells of a patient with a novel homozygous PAI-1 mutation. Stem Cell Research, 2016, 17, 657-660.	0.3	3
412	Pulmonary hospitalizations and ischemic heart disease events in patients with peripheral artery disease. Vascular Medicine, 2017, 22, 218-224.	0.8	3
413	Plasma acylcarnitines and progression of carotid artery atherosclerosis in HIV infection. Aids, 2019, 33, 1043-1052.	1.0	3
414	Cyclic guanosine monophosphate and 10-year change in left ventricular mass: the Multi-Ethnic Study of Atherosclerosis (MESA). Biomarkers, 2021, 26, 309-317.	0.9	3

#	Article	IF	Citations
415	Efficacy and safety of diuretics in heart failure with preserved ejection fraction: a scoping review. Heart, 2022, 108, 593-605.	1.2	3
416	A composite metric for predicting benefit from spironolactone in heart failure with preserved ejection fraction. ESC Heart Failure, 2021, 8, 3495-3503.	1.4	3
417	Glucose dysregulation and subclinical cardiac dysfunction in older adults: The Cardiovascular Health Study. Cardiovascular Diabetology, 2022, 21, .	2.7	3
418	Repolarization heterogeneity, diastolic dysfunction, and cardiovascular outcomes in heart failure with preserved ejection fraction. International Journal of Cardiology, 2016, 223, 116-117.	0.8	2
419	Inorganic vs. organic nitrates for heart failure with preserved ejection fraction: it's not all in your head!. European Journal of Heart Failure, 2017, 19, 1516-1519.	2.9	2
420	Heart Failure With Preserved Ejection Fraction and Obesity. JACC: Case Reports, 2020, 2, 28-32.	0.3	2
421	Association of Pericardial Fat with Cardiac Structure, Function, and Mechanics: The Multi-Ethnic Study of Atherosclerosis. Journal of the American Society of Echocardiography, 2022, 35, 579-587.e5.	1.2	2
422	Collagen homeostasis of the left atrium: an emerging treatment target to prevent heart failure?. European Journal of Heart Failure, 2022, 24, 332-334.	2.9	2
423	Inclusion Criteria for HFpEF Clinical Trials: Making the Case for Precision Diagnosis and Greater Inclusivity. Journal of Cardiac Failure, 2022, , .	0.7	2
424	A distinguishing feature. Journal of Hospital Medicine, 2007, 2, 39-45.	0.7	1
425	Electrocardiographic Predictors of Abnormal Left Ventricular Diastolic Function: Importance of the QTc Interval. Journal of Cardiac Failure, 2009, 15, S106.	0.7	1
426	Rasmussen-Torvik et al. Respond to â€œThe Perfect Measure of Diastolic Dysfunctionâ€• American Journal of Epidemiology, 2017, 185, 1231-1232.	1.6	1
427	New DEStiny Revealed. Circulation, 2018, 138, 1267-1271.	1.6	1
428	Evaluating Treatment Effect of Transcatheter Interatrial Shunt Device Using Heart Failure Event Ratesâ€”Reply. JAMA Cardiology, 2019, 4, 299.	3.0	1
429	Response by Kazi et al to Letter Regarding Article, â€œCost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathyâ€• Circulation, 2020, 142, e212-e213.	1.6	1
430	Embarking upon atrial fibrillation management in heart failure with preserved ejection fraction: Charting a course. Journal of Cardiovascular Electrophysiology, 2020, 31, 2284-2287.	0.8	1
431	Misfolded Transthyretin as a Novel Risk Factor for Heart Failure. JAMA Cardiology, 2021, 6, 255.	3.0	1
432	The splanchnic reservoir: an oasis for blood volume in heart failure with preserved ejection fraction?. European Journal of Heart Failure, 2021, 23, 1144-1146.	2.9	1

#	Article	IF	Citations
433	Abstract 15955: Widely Varying Prevalence of Diastolic Dysfunction by Different Classification Criteria: The Cardia Study. Circulation, 2014, 130, .	1.6	1
434	Rationale and Design of a Pharmacist-led Intervention for the Risk-Based Prevention of Heart Failure: The FIT-HF Pilot Study. Frontiers in Cardiovascular Medicine, 2021, 8, 785109.	1.1	1
435	Genetic variation in sodium glucose coâ€transporter 1 and cardiac structure and function at middle age. ESC Heart Failure, 2022, 9, 1496-1501.	1.4	1
436	Distribution of 10- and 30-Year Predicted Risks for Heart Failure in the US Population: National Health and Nutrition Examination Surveys 2015 to 2018. Circulation: Heart Failure, 2022, , CIRCHEARTFAILURE121009351.	1.6	1
437	Response to Letter Regarding Article, â€œEvaluating the Atrial Myopathy Underlying Atrial Fibrillation: Identifying the Arrhythmogenic and Thrombogenic Substrateâ€. Circulation, 2016, 133, e431.	1.6	0
438	Reply. JACC: Heart Failure, 2016, 4, 93.	1.9	0
439	Population-Based Studies of Invasive Hemodynamics. JAMA Cardiology, 2018, 3, 306.	3.0	0
440	Distribution and Correlates of Incident Heart Failure Risk in South Asian Americans: The MASALA Study. Journal of Cardiac Failure, 2021, 27, 1214-1221.	0.7	0
441	Association of Baseline Diuretic Use With Cardiovascular Outcomes in Patients With Heart Failure With Preserved Ejection Fraction: A Secondary Analysis From TOPCAT. Journal of Cardiac Failure, 2021, 27, 816-818.	0.7	0
442	Insulin Resistance Is Associated with Right Ventricular Dysfunction. Annals of the American Thoracic Society, 2022, 19, 562-571.	1.5	0
443	D-Dimer in the Months Leading up to Acute Coronary Events: A Case Crossover Study. Blood, 2014, 124, 2864-2864.	0.6	0
444	Cardiac Involvement: Evaluation and Management. , 2017, , 331-356.		0
445	Whole Exome Analyses to Examine the Impact of Rare Variants on Left Ventricular Traits in African American Participants from the HyperGEN and GENOA Studies. Journal of Hypertension and Management, 2017, 3, .	0.1	0
446	Risk Marker Fatigueâ€”Is There an Actionable Outcome?. JAMA Cardiology, 2021, 6, 78.	3.0	0
447	SNPs Filtered by Allele Frequency Improve the Prediction of Hypertension Subtypes. , 2021, , .		0
448	Title is missing!. , 2020, 15, e0240567.		0
449	Title is missing!. , 2020, 15, e0240567.		0
450	Title is missing!. , 2020, 15, e0240567.		0

#	Article	IF	Citations
451	Title is missing!. , 2020, 15, e0240567.		0